DBT & MRI for Dense Breasts: Reducing Cancer Deaths & False Positives in Women 40+

For women navigating the complexities of breast cancer screening, new research offers a nuanced perspective on the role of supplemental MRI alongside digital breast tomosynthesis (DBT). A study published March 2 in Annals of Internal Medicine suggests that for those aged 40 and older with extremely dense breasts, adding magnetic resonance imaging (MRI) to DBT can avert additional breast cancer deaths, though it also leads to a higher number of false-positive biopsy recommendations. This finding arrives at a time of ongoing debate about the optimal screening strategies for women with dense breast tissue, a condition that can obscure the detection of tumors on mammograms.

Understanding Breast Density and Screening Challenges

Breast density refers to the proportion of fibrous and glandular tissue compared to fatty tissue in the breasts. Women with extremely dense breasts face a higher risk of developing breast cancer and, crucially, a reduced sensitivity of mammography. This means that mammograms are less effective at detecting cancer in these women, increasing the likelihood of delayed diagnosis. Digital breast tomosynthesis, often called 3D mammography, improves upon traditional 2D mammography by creating a three-dimensional image of the breast, enhancing cancer detection rates. However, even with DBT, the challenge of detecting cancer in dense breasts persists.

MRI, uses magnetic fields and radio waves to create detailed images of the breast, offering a different approach to cancer detection. It’s particularly sensitive to detecting cancers that might be missed by mammography, but it also has a higher false-positive rate – meaning it can identify areas that appear suspicious but ultimately turn out to be benign. This can lead to unnecessary biopsies, which carry their own risks and anxieties.

The Study’s Findings: Balancing Benefits and Risks

The recent study in Annals of Internal Medicine sought to quantify the benefits and harms of adding supplemental MRI to DBT in women with dense breasts. Researchers analyzed data to determine the impact on both cancer deaths and false-positive biopsy rates. The findings indicate that while supplemental MRI can prevent additional deaths from breast cancer, it also results in more women being called back for further evaluation and undergoing biopsies that ultimately prove to be non-cancerous. The study did not specify the exact number of deaths averted or the increase in false positives, but highlighted the trade-off inherent in this screening approach.

It’s important to note that this study focuses specifically on women with extremely dense breasts. Breast density is categorized into four levels, and the benefits of supplemental MRI may not be the same for women with less dense breasts. The U.S. Preventive Services Task Force (USPSTF) is currently reviewing evidence on supplemental screening for women with dense breasts, as detailed in a systematic review published in Annals of Internal Medicine, and these findings will likely inform future recommendations.

What Does This Mean for Women and Their Clinicians?

The study doesn’t offer a simple “yes” or “no” answer to the question of whether women with dense breasts should undergo supplemental MRI. Instead, it underscores the need for individualized risk assessment and shared decision-making between patients and their healthcare providers. Factors to consider include a woman’s age, family history of breast cancer, genetic predispositions (such as BRCA mutations), and personal preferences regarding the potential benefits and harms of screening.

For women at high risk of breast cancer, the potential benefits of supplemental MRI may outweigh the risks of false-positive results. However, for women at lower risk, the added anxiety and inconvenience of MRI, along with the possibility of unnecessary biopsies, may not be justified. Medical Dialogues reports that breast MRI may offer added benefit for women with very dense breasts and high cancer risk.

Understanding False Positives and Biopsies

A false-positive result occurs when a screening test indicates the presence of cancer when none exists. This can happen with both mammography and MRI. When a suspicious area is identified, a biopsy is often recommended to determine whether it is cancerous. Biopsies involve removing a small sample of tissue for examination under a microscope. While biopsies are generally safe, they can cause discomfort, anxiety, and, in rare cases, complications such as infection or bleeding.

The Broader Context of Breast Cancer Screening

Current guidelines from organizations like the American Cancer Society recommend annual mammography screening for women aged 45 to 54 and the option to continue annual screening or switch to biennial screening for women 55 and older. These recommendations are based on extensive research demonstrating the effectiveness of mammography in reducing breast cancer mortality. However, the optimal screening strategy for women with dense breasts remains an area of active investigation.

The development of new technologies, such as artificial intelligence (AI) tools to improve mammogram interpretation, also holds promise for enhancing cancer detection rates and reducing false-positive results. Medical Xpress reports that MRI supplemental to digital breast tomosynthesis averts additional breast cancer deaths.

What comes next involves ongoing research to refine risk assessment models, evaluate the cost-effectiveness of different screening strategies, and develop more accurate and less invasive diagnostic tools. The USPSTF’s review of the evidence will be crucial in shaping future screening recommendations, and clinicians will need to stay abreast of these developments to provide the best possible care for their patients.